Monitor progress on technology transfer across Lantheus’ PET manufacturing facilities and adoption of PYLARIFY TruVu post-launch; any supply chain improvements could enhance margins, but near-term financial impact is limited.
Price Chart
Executive Summary
Lantheus Holdings received FDA approval for PYLARIFY TruVu, a new formulation of its leading PSMA PET imaging agent for prostate cancer, designed to improve manufacturing efficiency, increase batch sizes, and expand patient access. The product is expected to launch in Q4 2026 with a phased rollout, maintaining the same diagnostic performance as the original PYLARIFY. This approval supports supply scalability but does not represent a clinical advancement.
Key Facts
- FDA approved PYLARIFY TruVu, a new formulation of piflufolastat F 18, for PET imaging in men with suspected metastatic or recurrent prostate cancer.
- The new formulation is designed for improved manufacturing efficiency and larger batch sizes, supporting broader geographic distribution.
- PYLARIFY TruVu has the same diagnostic properties, safety, and effectiveness as the original PYLARIFY.
- Commercial launch expected in Q4 2026 with a phased geographic rollout.
- No new clinical data was generated; approval was based on existing OSPREY and CONDOR trial data via the 505(b)(2) pathway.
Financial Impact
Potential for improved operating leverage and supply chain scalability, but no immediate revenue uplift expected before 2026 launch.
Risk Factors
- Execution risk in rolling out the new formulation across the PMF network without supply disruption.
- Uncertainty around payer coverage and customer transition from original PYLARIFY to TruVu.
- No clinical differentiation may limit pricing or reimbursement advantages.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251298 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $100.10 $99.80 | ▼ −0.30% | ▲ +0.22% | $100.15 (+0.05%) |
Oct 2, 2026 25d ago | DEFA14A | $100.19 $99.95 | ▼ −0.24% | ▼ −0.79% | $100.15 (−0.04%) |
Oct 2, 2026 25d ago | 8-K | $100.19 $99.95 | ▼ −0.24% | ▼ −0.79% | $100.15 (−0.04%) |
Sep 16, 2026 5w ago | DEFA14A | $100.80 $100.55 | ▼ −0.25% | ▼ −0.38% | $100.15 (−0.64%) |
Aug 26, 2026 8w ago | PREM14A | $100.82 $100.47 | ▼ −0.35% | ▼ −1.00% | $100.15 (−0.66%) |
Aug 14, 2026 10w ago | Press Release | $100.95 $100.91 | ▼ −0.04% | ▲ +0.43% | $100.15 (−0.79%) |
Aug 6, 2026 11w ago | 8-K | $101.07 $100.95 | ▼ −0.12% | ▼ −0.73% | $100.15 (−0.91%) |
Aug 3, 2026 12w ago | 8-K / DEFA14A | $101.11 $101.50 | ▲ +0.39% | ▲ +0.59% | $100.15 (−0.95%) |
Aug 3, 2026 12w ago | DEFA14A / 8-K | $101.19 $101.11 | ▼ −0.08% | ▼ −1.88% | $100.15 (−1.03%) |
Aug 3, 2026 12w ago | Press Release | $101.19 $101.11 | ▼ −0.08% | ▼ −1.88% | $100.15 (−1.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers